Luana Lugini was born in Rome on March 5, 1976. In 2000, she graduated with honors in biological sciences, biotechnology specialization, from University of Rome "La Sapienza," Rome, Italy. In 2005, she completed her studies getting Ph.D. degree in experimental physiopathology at the Medicine Faculty, University of Rome, Tor Vergata. From 2000 to 2002 she worked at the Section of Tumour Immunology, Istituto Superiore di Sanità (ISS) to study (i) the interaction between actin cytoskeleton proteins and death receptors in T human lymphocytes and natural killer (NK) cells, (ii) drug resistance in human melanoma cell lines, and (iii) adoptive immunotherapy based on the use of NK cells in immunodeficient mice. In 2003 she registered a Patent (by IMED AB, 103 95 Stockholm, SWEDEN) consisting of a diagnostic test for the identification and evaluation of metastatic tumours. In 2003 she was awarded the "First Prize Onlus AICC 2003," reserved to young researchers, conferred by Italian Association of Cell Culture. She was also granted a triennial fellowship of Italian Federation of Cancer Research. In this period her research was mainly focused on human tumour immune escape mechanisms and in particular (i) the secretion of tumour exosomes bearing death receptors and (ii) tumour "cannibalic" activity, used by metastatic melanoma cells to entrap and digest live T lymphocytes. From 2005 she has a permanent position at the ISS, where she works as Researcher. Up till now her main research interests are tumour biology, cancer, NK cells-derived exosomes, and development of innovative anticancer strategies based on the use of antiacid drugs (PPI). She is author of 29 abstracts for National and International Conferences. She is author of 21 publications in international peer-reviewed journals.
Biography Updated on 30 April 2013